Pipeline

NeurogesX is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Our initial focus is on chronic peripheral neuropathic pain, which includes the conditions of postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP), and painful diabetic neuropathy (PDN) and potentially other neuropathic pain indications.

NeurogesX Pipeline

Qutenza® (capsaicin) 8% patch, is a dermal delivery system containing a prescription strength of capsaicin that is currently approved in the United States and the European Union.

NGX-1998, a high-concentration, dermal liquid formulation of capsaicin designed to provide rapid, localized and sustained pain relief to treat peripheral neuropathic pain conditions. We have filed an Investigational New Drug application (IND) for NGX-1998 and completed three Phase 1 studies.

In addition, we have conducted preclinical evaluations for an opioid prodrug program and an analgesic prodrug program for managing additional chronic and acute pain conditions.